switching from semaglutide to tirzepatide dose between weight-loss medications Switch Ozempic to Tirzepatide: Clinical

Food and Drug Administration (FDA) expected to approve Tirzepatide for weight loss later this year

Topline data from the Phase 3 REDEFINE 1 trial found CagriSema, a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss versus placebo in adults with 1 Announced by Novo Nordisk on December 20, 2024, the trial achieved its primary endpoint with a superior weight loss of 22.7% after 68 weeks of treatment but still fell short of the 25% weight loss expected by the company in earlier discussions

Whats more, theres also limited knowledge on the long-term effects of the procedure, which is why many eye doctors advise against the use of iris implants for a change in eye colour

In other words, even in older patients with frailty, reducing the incidence of MACE and hospitalization for heart failure may be possible by continuing SGLT2 inhibitors with careful follow-up